Адаптована клінічна настанова, заснована на доказах (стр. 47 )

67. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829–38.

68. Rutgeerts P, D'Haens G, Van Assche G, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe Crohn's disease. First results of the EXTEND trial. Gastroenterology 2009;136:A116 abstract.

69. Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129(3):807–18.

70. Colombel JF, Hébuterne X. Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial. Am J Gastroenterol 2008;103:A1107 abstract.

71. Rutgeerts P, Van Assche G, Vermeire S. Optimising anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593–610.

72. Colombel JF, Loftus Jr EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19–31.

73. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.33.

74. Keane J, Gershon S, Wise RP, Mirabile-Levens E. Tuberculosis associated with infliximab, a tumour necrosis factor alphaneutralizing agent. N Engl J Med 2001;345:1098–104.

75. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7: 874–81.

76. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of anti-tumor necrosis factor agents in Crohn's disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644–53.

77. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542–53.

78. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136: 1182–97.

79. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912–25.

80. Targan SR, Feagan BG, Fedorak RN, et al. International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology May 2007;132(5):1672–83.

81. Hommes D, Mikhajlova T, Stoinov S, et al. Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe crohn's disease. Gastroenterology 2004;127:332.

82. Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanized antiinterferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55:1138–44 207.

83. Mannon PJ, Fuss I, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069–79.

84. Sandborn WJ, Feagan BG, Fedorak RN, et al. Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130–41 160.

85. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomised trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989–96.

86. Braat H, Rottiers P, Huyghebaert N, et al. Interleukin-10 producing Lactococcus lactis for the treatment of Crohn's disease. Gastroenterology 2005;128(Suppl 2):A-104.

87. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133–45.

88. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6- mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000(2):CD000545.

89. Sandborn W, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathiorpine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999;117:527–35.

90. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate in the treatment of Crohn's disease. N Engl J Med 1995;332:292–7.

91. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease (Cochrane Review). Cochrane Database Syst Rev 2003(1):CD003459.

92. Fraser AG. Methotrexate: first or second-line immunomodulator? Eur J Gastroenterol Hepatol 2003;15:225–31.

93. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627–32.

94. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral bcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:57–63.

95. Hamilton RA, Kremer JM. Why intramuscular dosing may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86–90.

96. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004;43:267–71.

97. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95:3150–6.

98. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989;321:845–50.

99. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994;330:1846–51.

100. Jewell DP, Lennard-Jones RE. Oral cyclosporine for chronic active Crohn's disease: a multi-centre controlled trial. Eur J Gastroenterol Hepatol 1994;6:499–506.

101. Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G, Smith PR. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. Gastroenterology 1995;109:774–82.

102. Hermida-Rodriguez C, Cantero Perona J, Garcia-Valriberas R, et al. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastroenterology 1999;46:2265–8.

103. Santos JV, Baudet JA, Casellas FJ, et al. Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease. Short - and long-term results. J Clin Gastroenterol 1995;20: 207–10.

104. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998;93:442–8.

105. Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus longterm therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001;15:371–7

106. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998;93:1860–6.

107. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997;92: 876–9.

108. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2001(3):CD000542.

109. Gassull MA, Cabre E. Nutrition in inflammatory bowel disease. Curr Opin Nutr Metab Care 2001;4:561–9.

110. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2003;15:401–8.

111. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424–31.

112. Breuer-Katschinski BD, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:225–8.

113. Nagy F, Molnar T, Szepes Z, et al. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J Gastroenterol 2008;14:4342–6.

114. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674–8.

115. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002;359:1541–9.

116. Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054–61.

117. Lémann M, Mary JY, Colombel J-F, et al. A randomized, doubleblind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812–8.

118. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7: 80–5.

119. Kandiel A, Fraser AG, Korrelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54: 1121–5.

120. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374(9701):1617–25.